Subtopic Deep Dive
Cytomegalovirus Antiviral Therapy
Research Guide
What is Cytomegalovirus Antiviral Therapy?
Cytomegalovirus antiviral therapy encompasses antiviral agents like ganciclovir, valganciclovir, foscarnet, and letermovir for preventing and treating CMV infections in immunocompromised patients such as transplant recipients.
Key drugs include valganciclovir, shown superior to oral ganciclovir for CMV prevention in solid organ transplant recipients (Payá et al., 2004, 876 citations). Letermovir prophylaxis significantly reduces clinically significant CMV infection in hematopoietic-cell transplantation (Marty et al., 2017, 1139 citations). Consensus guidelines outline management strategies in solid-organ transplantation (Kotton et al., 2018, 1098 citations). Over 20 papers from the provided list address therapy efficacy and resistance.
Why It Matters
CMV antiviral therapy prevents severe disease in transplant recipients, reducing graft loss and mortality (Kotton et al., 2018). Letermovir prophylaxis lowered CMV infection risk by targeting the terminase complex, addressing ganciclovir resistance (Marty et al., 2017). Valganciclovir improved bioavailability over ganciclovir, enabling oral prophylaxis in high-risk solid organ transplants (Payá et al., 2004). These advances impact 100,000+ annual transplant patients worldwide, curbing antiviral resistance and improving survival rates.
Key Research Challenges
Antiviral Drug Resistance
Rising resistance to ganciclovir and foscarnet in transplant patients complicates treatment (Kotton et al., 2018). Letermovir offers an alternative but resistance mutations emerge post-prophylaxis (Marty et al., 2017). Profiling UL97 and UL54 mutations is essential for therapy selection.
Pharmacokinetics in Hosts
Drug levels vary in immunocompromised patients due to organ dysfunction and interactions (Payá et al., 2004). Valganciclovir achieves higher ganciclovir exposure than oral ganciclovir but requires monitoring (Payá et al., 2004). Optimizing dosing prevents toxicity and underdosing.
Combination Therapy Needs
Single agents fail against resistant strains, necessitating combinations with immune therapies (Griffiths et al., 2014). Guidelines recommend sequencing letermovir after failure of DNA polymerase inhibitors (Kotton et al., 2018). Trials for novel agent synergies remain limited.
Essential Papers
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
Francisco M. Marty, Per Ljungman, Roy F. Chemaly et al. · 2017 · New England Journal of Medicine · 1.1K citations
Letermovir prophylaxis resulted in a significantly lower risk of clinically significant CMV infection than placebo. Adverse events with letermovir were mainly of low grade. (Funded by Merck; Clinic...
The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation
Camille N. Kotton, Deepali Kumar, Angela M. Caliendo et al. · 2018 · Transplantation · 1.1K citations
Despite recent advances, cytomegalovirus infections remain one of the most common complications affecting solid organ transplant recipients, conveying higher risks of complications, graft loss, mor...
Efficacy and Safety of Valganciclovir vs. Oral Ganciclovir for Prevention of Cytomegalovirus Disease in Solid Organ Transplant Recipients
Carlos V. Payá, Atul Humar, Ed Dominguez et al. · 2004 · American Journal of Transplantation · 876 citations
Subversion of Cellular Autophagosomal Machinery by RNA Viruses
William T. Jackson, Thomas H. Giddings, Matthew P. Taylor et al. · 2005 · PLoS Biology · 800 citations
Infection of human cells with poliovirus induces the proliferation of double-membraned cytoplasmic vesicles whose surfaces are used as the sites of viral RNA replication and whose origin is unknown...
Infection in Organ Transplantation
J. A. Fishman · 2017 · American Journal of Transplantation · 753 citations
Intrauterine Transmission of Cytomegalovirus to Infants of Women with Preconceptional Immunity
Suresh B. Boppana, Lisa B. Rivera, Karen B. Fowler et al. · 2001 · New England Journal of Medicine · 734 citations
In women who are seropositive for CMV, reinfection with a different strain of CMV can lead to intrauterine transmission and symptomatic congenital infection.
Immunosenescence: molecular mechanisms and diseases
Zaoqu Liu, Qimeng Liang, Yuqing Ren et al. · 2023 · Signal Transduction and Targeted Therapy · 687 citations
Abstract Infection susceptibility, poor vaccination efficacy, age-related disease onset, and neoplasms are linked to innate and adaptive immune dysfunction that accompanies aging (known as immunose...
Reading Guide
Foundational Papers
Start with Payá et al. (2004) for valganciclovir vs ganciclovir comparison establishing oral prophylaxis standards; Griffiths et al. (2014) for CMV pathogenesis informing therapy targets.
Recent Advances
Marty et al. (2017) for letermovir phase 3 trial data; Kotton et al. (2018) for updated SOT management consensus.
Core Methods
Prophylaxis (letemovir terminase inhibition), preemptive therapy (valganciclovir DNA polymerase block), resistance genotyping (UL97/UL54 sequencing), pharmacokinetics monitoring (AUC dosing).
How PapersFlow Helps You Research Cytomegalovirus Antiviral Therapy
Discover & Search
Research Agent uses searchPapers and exaSearch to find letermovir trials like Marty et al. (2017), then citationGraph reveals 1139 citing papers on resistance. findSimilarPapers identifies analogs to Kotton et al. (2018) guidelines for transplant protocols.
Analyze & Verify
Analysis Agent applies readPaperContent to extract pharmacokinetics data from Payá et al. (2004), then runPythonAnalysis with pandas computes AUC comparisons across studies. verifyResponse via CoVe and GRADE grading verifies resistance rates against Marty et al. (2017) endpoints.
Synthesize & Write
Synthesis Agent detects gaps in combination therapy evidence from Griffiths et al. (2014), flags contradictions in resistance data. Writing Agent uses latexEditText, latexSyncCitations for Marty et al. (2017), and latexCompile to generate review manuscripts; exportMermaid diagrams letermovir mechanisms.
Use Cases
"Extract CMV resistance mutation frequencies from transplant trials and plot trends."
Research Agent → searchPapers('CMV resistance UL97') → Analysis Agent → readPaperContent(Kotton 2018) → runPythonAnalysis(pandas plot mutation rates over time) → matplotlib trend graph output.
"Draft LaTeX review on letermovir vs ganciclovir in HCT patients."
Synthesis Agent → gap detection(Marty 2017, Payá 2004) → Writing Agent → latexEditText(structure sections) → latexSyncCitations → latexCompile(PDF with figures) → output formatted review.
"Find open-source code for CMV viral load modeling from papers."
Research Agent → paperExtractUrls(citationGraph Marty 2017) → paperFindGithubRepo → Code Discovery → githubRepoInspect(viral kinetics simulator) → output runnable Python model.
Automated Workflows
Deep Research workflow scans 50+ papers via searchPapers on 'letemovir resistance', chains citationGraph to Marty et al. (2017), produces GRADE-graded systematic review report. DeepScan applies 7-step analysis with CoVe checkpoints to Kotton et al. (2018) guidelines, verifying prophylaxis efficacy stats. Theorizer generates hypotheses on novel combinations from Payá et al. (2004) pharmacokinetics data.
Frequently Asked Questions
What is cytomegalovirus antiviral therapy?
It involves drugs like ganciclovir, valganciclovir, foscarnet, and letermovir to treat or prevent CMV in immunocompromised hosts. Valganciclovir replaced oral ganciclovir for better bioavailability (Payá et al., 2004).
What are main methods in CMV therapy?
Prophylaxis with letermovir in HCT (Marty et al., 2017) and preemptive valganciclovir in SOT per guidelines (Kotton et al., 2018). Resistance testing guides switches to foscarnet.
What are key papers?
Marty et al. (2017, 1139 citations) on letermovir prophylaxis; Kotton et al. (2018, 1098 citations) on SOT guidelines; Payá et al. (2004, 876 citations) on valganciclovir efficacy.
What are open problems?
Developing agents beyond DNA polymerase inhibitors due to resistance; optimizing combinations; addressing congenital CMV therapy gaps (Boppana et al., 2001).
Research Cytomegalovirus and herpesvirus research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Cytomegalovirus Antiviral Therapy with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers